The Biology of Anthrax

International Conference


Dr M. Worth Calfee – EPA, USA
Development of Sampling Capabilities to Support Large-Scale Anthrax Incident Response

Dr Antonio Fasanella – Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata,
Foggia, Italy
Welcome Address

David Hipkiss – Enesi Pharma, UK
ImplaVax® Novel Solid Dose Vaccine Technology – Delivering Improved Thermal Stability and
Performance with Ultimate Convenience

Dr Alex Hoffmaster – CDC, USA
Genomic Characterization and Copy Number Variation of Bacillus anthracis Plasmids pXO1 and
pXO2 in a Historical Collection of 412 Strains

Prof Martin Hugh Jones – Louisiana State University
Some Anthrax Experiences

Dr Michael Merchlinsky – BARDA, USA
Regulatory Path for Anthrax Therapeutics: Application of the FDA Animal Rule

Dr David Johnson – Health and Safety Executives, UK
UK Regulatory Perspective on Working with Bacillus anthracis

Dr Gilles Vergnaud – Institute for Integrative Biology of the Cell, France
Bacillus anthracis Evolutionary History: Taking Advantage of Polytomies and Human History to
Propose Dating Points

Dr Chia-Wei Tsai – BARDA, USA
Establishing Preparedness against Anthrax: Enhancement in the USG Countermeasure Portfolio since
the Amerithrax Attacks in 2001